Alastair Thomson

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.6K citations

Pharmacy, Oncology, Pharmacotherapy +17

Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)

Steve Nicholson, Emma Hall, S.J. Harland et al. · British Journal of Cancer · 2013 · 135 citations · Full text

Medicine, Oncology, Pharmacology +17

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory et al. · The Lancet Oncology · 2023 · 81 citations · Full text

Medicine, Oncology, Pharmacology +11

Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP

Martin R. Stockler, Andrew Martin, Ian D. Davis et al. · Journal of Clinical Oncology · 2021 · 60 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).

Ian D. Davis, Andrew Martin, Robert Zielinski et al. · Journal of Clinical Oncology · 2022 · 53 citations

Medicine, Oncology, Pharmacotherapy +17